Literature DB >> 23764695

Targeting tumor hypoxia with 2-nitroimidazole-indocyanine green dye conjugates.

Yan Xu1, Saeid Zanganeh, Innus Mohammad, Andres Aguirre, Tianheng Wang, Yi Yang, Liisa Kuhn, Michael B Smith, Quing Zhu.   

Abstract

Tumor hypoxia is a major indicator of treatment resistance to chemotherapeutic drugs, and fluorescence optical tomography has tremendous potential to provide clinically useful, functional information by identifying tumor hypoxia. The synthesis of a 2-nitroimidazole-indocyanine green conjugate using a piperazine linker (piperazine-2-nitroimidazole-ICG) capable of robust fluorescent imaging of tumor hypoxia is described. In vivo mouse tumor imaging studies were completed and demonstrate an improved imaging capability of the new dye relative to an earlier version of the dye that was synthesized with an ethanolamine linker (ethanolamine-2-nitroimidazole-ICG). Mouse tumors located at imaging depths of 1.5 and 2.0 cm in a turbid medium were imaged at various time points after intravenous injection of the dyes. On average, the reconstructed maximum fluorescence concentration of the tumors injected with piperazine-2-nitroimidazole-ICG was twofold higher than that injected with ethanolamine-2-nitroimidazole-ICG within 3 h postinjection period and 1.6 to 1.7 times higher beyond 3 h postinjection. The untargeted bis-carboxylic acid ICG completely washed out after 3 h postinjection. Thus, the optimal window to assess tumor hypoxia is beyond 3 h postinjection. These findings were supported with fluorescence images of histological sections of tumor samples and an immunohistochemistry technique for identifying tumor hypoxia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23764695      PMCID: PMC3680745          DOI: 10.1117/1.JBO.18.6.066009

Source DB:  PubMed          Journal:  J Biomed Opt        ISSN: 1083-3668            Impact factor:   3.170


  28 in total

1.  Experimental three-dimensional fluorescence reconstruction of diffuse media by use of a normalized Born approximation.

Authors:  V Ntziachristos; R Weissleder
Journal:  Opt Lett       Date:  2001-06-15       Impact factor: 3.776

2.  In vivo optical imaging of membrane-type matrix metalloproteinase (MT-MMP) activity.

Authors:  Lei Zhu; Fan Zhang; Ying Ma; Gang Liu; Kwangmeyung Kim; Xuexun Fang; Seulki Lee; Xiaoyuan Chen
Journal:  Mol Pharm       Date:  2011-11-01       Impact factor: 4.939

3.  Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody.

Authors:  Sabrina Oliveira; Guus A M S van Dongen; Marijke Stigter-van Walsum; Rob C Roovers; Jord C Stam; Willem Mali; Paul J van Diest; Paul M P van Bergen en Henegouwen
Journal:  Mol Imaging       Date:  2012-02       Impact factor: 4.488

4.  Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry.

Authors:  Ly-Binh-An Tran; Anne Bol; Daniel Labar; Bénédicte Jordan; Julie Magat; Lionel Mignion; Vincent Grégoire; Bernard Gallez
Journal:  Radiother Oncol       Date:  2012-06-06       Impact factor: 6.280

5.  Diamine-free lithiation-trapping of N-Boc heterocycles using s-BuLi in THF.

Authors:  Graeme Barker; Peter O'Brien; Kevin R Campos
Journal:  Org Lett       Date:  2010-09-17       Impact factor: 6.005

6.  Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.

Authors:  Chi B Vu; Bo Peng; Gnanasambandam Kumaravel; Glenn Smits; Xiaowei Jin; Deepali Phadke; Thomas Engber; Carol Huang; Jennifer Reilly; Stacy Tam; Donna Grant; Gregg Hetu; Liqing Chen; Jianbo Zhang; Russell C Petter
Journal:  J Med Chem       Date:  2004-08-12       Impact factor: 7.446

Review 7.  Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology.

Authors:  Scott B Raymond; Jesse Skoch; Ivory D Hills; Evgueni E Nesterov; Timothy M Swager; Brian J Bacskai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

Review 8.  Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia.

Authors:  R J Hodgkiss
Journal:  Anticancer Drug Des       Date:  1998-09

9.  Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans.

Authors:  Alper Corlu; Regine Choe; Turgut Durduran; Mark A Rosen; Martin Schweiger; Simon R Arridge; Mitchell D Schnall; Arjun G Yodh
Journal:  Opt Express       Date:  2007-05-28       Impact factor: 3.894

10.  Computed tomography-guided time-domain diffuse fluorescence tomography in small animals for localization of cancer biomarkers.

Authors:  Kenneth M Tichauer; Robert W Holt; Kimberley S Samkoe; Fadi El-Ghussein; Jason R Gunn; Michael Jermyn; Hamid Dehghani; Frederic Leblond; Brian W Pogue
Journal:  J Vis Exp       Date:  2012-07-17       Impact factor: 1.355

View more
  6 in total

1.  In vivo photoacoustic tumor tomography using a quinoline-annulated porphyrin as NIR molecular contrast agent.

Authors:  Michael Luciano; Mohsen Erfanzadeh; Feifei Zhou; Hua Zhu; Tobias Bornhütter; Beate Röder; Quing Zhu; Christian Brückner
Journal:  Org Biomol Chem       Date:  2017-01-25       Impact factor: 3.876

2.  Targeting tumor hypoxia: a third generation 2-nitroimidazole-indocyanine dye-conjugate with improved fluorescent yield.

Authors:  Feifei Zhou; Saeid Zanganeh; Innus Mohammad; Christopher Dietz; Akram Abuteen; Michael B Smith; Quing Zhu
Journal:  Org Biomol Chem       Date:  2015-12-14       Impact factor: 3.876

3.  Indocyanine green enhanced co-registered diffuse optical tomography and photoacoustic tomography.

Authors:  Chen Xu; Patrick D Kumavor; Umar Alqasemi; Hai Li; Yan Xu; Saeid Zanganeh; Quing Zhu
Journal:  J Biomed Opt       Date:  2013-12       Impact factor: 3.170

4.  Enhanced fluorescence diffuse optical tomography with indocyanine green-encapsulating liposomes targeted to receptors for vascular endothelial growth factor in tumor vasculature.

Authors:  Saeid Zanganeh; Yan Xu; Carl V Hamby; Marina V Backer; Joseph M Backer; Quing Zhu
Journal:  J Biomed Opt       Date:  2013-12       Impact factor: 3.170

Review 5.  Biomarkers in preclinical cancer imaging.

Authors:  Monique R Bernsen; Klazina Kooiman; Marcel Segbers; Fijs W B van Leeuwen; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

6.  In vitro and in vivo analysis of indocyanine green-labeled panitumumab for optical imaging-a cautionary tale.

Authors:  Yang Zhou; Young-Seung Kim; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2014-10-03       Impact factor: 4.774

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.